-
Top 100 domestic pharmaceutical companies' product R&D rankings announced: Junshi, Hengrui, CanSino...
Time of Update: 2022-08-15
In recent years, driven by a series of drug administration reforms and the national science and technology innovation strategy, the research and development of innovative drugs has been in full swing
-
Deconstructing the Six Variables of Normalized Medical Reform
Time of Update: 2022-08-15
The state takes the establishment of a normalized and institutionalized centralized procurement mechanism, the establishment and improvement of a long-term mechanism for fund supervision, the establishment and improvement of treatment guarantee policies, deepening the reform of medical service prices, deepening the reform of medical insurance payment methods, and carrying out medical insurance drug catalog negotiations and standardized management as reforms.
-
Novo Nordisk, Eli Lilly, Dongyang Sunshine, etc. share the market of tens of billions, and the main battlefield of insulin is outside the standard!
Time of Update: 2022-08-15
Compared with the siege of chemical drugs, domestic companies face such a huge insulin market, and the market competition with foreign capital before centralized procurement is lackluster .
-
Focusing on the innovation and cooperation of South China Pharmaceuticals, the September CPhI & P-MEC China Guangzhou Station is scheduled!
Time of Update: 2022-08-15
[Pharmaceutical Network Exhibition Report] In recent years, the scale of Guangdong's pharmaceutical and health industry has grown steadily, the industrial structure has been continuously optimized, a
-
200 first generic drugs will be approved!
Time of Update: 2022-08-15
. Table 2: Top 10 products that are popular for imitation listings Figure 1: Global and domestic sales of the three major products in 2021 In 2017, Novartis' sacubitril and valsartan sodium tablets were approved for import, and in 2019, they entered the national medical insurance negotiation catalog and their sales increased rapidly In 2021, the total sales of Chinese public medical institution terminals, Chinese urban physical pharmacy terminals and Chinese online pharmacy terminals will exceed 2 billion yuan.
-
Traditional Chinese Medicine: A protracted battle against greed, the key to victory is "the easiest"
Time of Update: 2022-08-15
It is the root cause of the good quality trend of traditional Chinese medicine products From the national drug sampling inspection annual reports over the years, we can find out the reason for the fundamental change in the qualification rate of Chinese herbal medicines.
-
The B certificate application process is optimized, and the trustee GMP certificate is exempted!
Time of Update: 2022-08-15
The flow of approval documents between provinces has been ignited at the policy level . Since mid-May, four provinces of Anhui, Sichuan, Hebei and Shanxi have issued relevant policies that are conduc
-
Industry: The Chinese herbal medicine market may gradually become polarized in the future
Time of Update: 2022-08-15
In the old version, only ginseng, licorice, astragalus and other varieties stipulated the limit standards for 9-22 kinds of organochlorine pesticide residues, while the new version of the pharmacopoeia for heavy metals and banned pesticides The general requirements for the plant medicinal materials included in the pharmacopoeia have reached the standard.
-
New standards are coming, and the outlook for the standard system of pharmaceutical packaging materials in the 2025 edition of the Chinese Pharmacopoeia
Time of Update: 2022-08-15
Looking forward to the general technical requirements for the standard system of pharmaceutical packaging materials that may be included in the 2025 edition of the Chinese Pharmacopoeia, the list is as follows: 3 summary The Chinese Pharmacopoeia standards have received extensive attention from all parties involved in the research and development, production, use, review and supervision of pharmaceutical packaging materials and drugs .
-
Layoffs, delisting, bankruptcy!
Time of Update: 2022-08-15
The overseas capital market has responded quickly, and some Biotech companies have come to an end: On April 8, 2022, Kaleido Biosciences, an American microbial pharmaceutical company, filed an application announcing its intention to cease operations, lay off remaining employees and delist from the Nasdaq exchange .
-
This field of rare diseases has ushered in new treatment options, which are independently developed by domestic pharmaceutical companies!
Time of Update: 2022-08-15
. Recently, there is good news that ABSK021, a highly selective CSF-1R inhibitor independently developed by Heyu Pharma, has been recognized by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China as a breakthrough therapy drug for the treatment of inoperable tenosynovial giant cells.
-
More than 10 pharmaceutical companies announced their "transcripts" in the first half of the year, and many net profits doubled
Time of Update: 2022-08-15
. In the first half of 2022, the company achieved revenue of 642 million yuan, a year-on-year increase of 41.
97%, and profitability accelerated In the first half of 2022, the company achieved revenue of 642 million yuan, a year-on-year increase of 41.
-
Within a week, many pharmaceutical companies have reported reviews, including Shanghai Pharmaceuticals, Zhejiang Pharmaceuticals, etc.
Time of Update: 2022-08-15
. Shanghai Pharmaceuticals: Folic Acid Tablets Passed Consistency Evaluation of Generic Drugs Shanghai Pharmaceuticals announced on August 4 that Changzhou Pharmaceutical Factory, a subsidiary of the company, recently received the "Approval Notice for Supplementary Drug Application" issued by the State Food and Drug Administration.
-
Full of goodies!
Time of Update: 2022-08-15
From researcher Zhang Lan, director of the Water Quality and Health Monitoring Office of the China Institute of Disease Control and Environment, Liu Li, ICP-MS technical support for PerkinElmer's inorganic production line, and Ma Jiping, director of the School Analysis and Testing Center, Deputy Dean of the School of Environmental and Municipal Engineering, Qingdao University of Technology Participated in this online forum and made relevant interpretations on the content of the new GB 5749 standard .
-
Orphan drugs will account for 1/3 of the global drug pipeline value, how will domestic research and development go?
Time of Update: 2022-08-15
Favorable policies work together to promote the domestic orphan drug market Therefore, in recent years, China has successively introduced various types of supporting policies related to rare disease diagnosis, drug development and registration, medical security, taxation, etc.
-
Through license out, ADC drugs are speeding up to the sea!
Time of Update: 2022-08-15
In May of this year, Kelun Pharmaceutical announced a paid exclusive license to Merck to develop, manufacture and commercialize the ADC drug SKB-264 targeting TROP2 outside China (including mainland China, Hong Kong, Macau and Taiwan) .
-
Announcement on the draft standard of magnesium trisilicate, disodium edetate, aluminum hydroxide and powdered cellulose pharmaceutical excipients
Time of Update: 2022-08-15
pdf Our committee plans to revise the standards for pharmaceutical excipients of magnesium trisilicate, disodium edetate, aluminum hydroxide and powdered cellulose.
pdf Our committee plans to revise the standards for pharmaceutical excipients of magnesium trisilicate, disodium edetate, aluminum hydroxide and powdered cellulose.
-
Under the centralized procurement, the consistency evaluation of generic drugs is actively promoted
Time of Update: 2022-08-15
Lisheng Pharmaceutical announced at noon on May 5 that recently, the company received the "Approval Notice for Supplementary Drug Application" issued by the State Food and Drug Administration for Donepezil Hydrochloride Tablets 5mg, which passed the quality and efficacy consistency evaluation of generic drugs .
-
In 2021, there are no Chinese pharmaceutical companies in the top ten global generic drug companies. Where is the spring of domestic generic drugs?
Time of Update: 2022-08-15
Teva -- sales have fallen for 5 years in a row Teva Pharmaceuticals is a global pharmaceutical company headquartered in Israel and one of the largest generic drug manufacturers in the world.
-
The 2021 drug review report is released!
Time of Update: 2022-08-15
The "Report" shows that in 2021, the Drug Evaluation Center of the State Drug Administration will accept 11,658 registration applications, a year-on-year increase of 13.
The "Report" shows that in 2021, the Drug Evaluation Center of the State Drug Administration will accept 11,658 registration applications, a year-on-year increase of 13.
